Neoadjuvant chemotherapy for ewing's sarcoma of bone: No benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase -results of two sequential studies

Cancer

Volumn 82, Issue 6, 1998, Pages 1174-1183

  Bacci, Gaetano ^a   Picci, Piero ^a   Ferrari, Stefano ^a   Mercuri, Mario ^a   Del Prever, Adalberto Brach ^b   Rosito, Pasquale ^b   Barbieri, Enza ^c   Tienghi, Amelia ^d   Forni, Cristiana ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Ravenna Hospital   (Italy)

Author keywords

Bone; Ewing's sarcoma; Neoadjuvant chemotherapy; Pediatric tumors

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHROTOXICITY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; NEOPLASM RECURRENCE, LOCAL; SARCOMA, EWING'S; VINCRISTINE;

EID: 0032520764     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1174::AID-CNCR24>3.0.CO;2-2     Document Type: Article

References (32)

1. Jaffe N, Traggis D, Salian S, Cassady JR. Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D, cyclophosphamide) and radiation therapy. Cancer 1976;38:1925-30.
2. Rosen G, Caparros B, Nirenberg A, Marcove RC, Huvos AG, Kosloff C, et al. Ewing's sarcoma: ten-year experience with adjuvant chemotherapy. Cancer 1981;47:2204-13.
3. Jurgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer 1988;61:23-32.
4. Bacci G, Toni A, Avella M, Manfrini M, Sudanese A, Ciaroni D, et al. Long term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 1989; 63:1477-86.
5. Burgert EO, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol 1990;8:1514-24.
6. Nesbit ME, Gehan EA, Burgert EO, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first Intergroup Study. J Clin Oncol 1990;8:1664-74.
7. Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver-McClure L, et al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys 1991;20:389-95.
8. Dunst J, Sauer R, Burgers MV, Hawliczek R, Kurtens R, Winkelmann W, et al., and the Cooperative Ewing's Sarcoma Study Group. Radiation therapy as local treatment in Ewing's sarcoma: results of the cooperative Ewing's sarcoma studies CESS 81 and CESS 86. Cancer 1991;67:2818-25.
9. Hayes FA, Thompson EJ, Meyer WH, Kun L, Parham D, Rao B, et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol 1989;7:208-13.
10. Bacci G, Campanacci M, Pagani PA. Adjuvant chemotherapy in the treatment of clinically localised Ewing's sarcoma. J Bone Joint Surg Am 1978;60:567-74.
11. Oberlin O, Habrand JL, Zucker JM, Brunat-Mentigny M, Terrier-Lacombe MJ, et al. No benefit of Ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1407-12.
12. Bacci G, Picci P, Avella M, Ferrari S, Barbieri E, Manfrini M, et al Neoadjuvant chemotherapy for localized Ewing's sarcoma of bone: experience at the Istituto Ortopedico Rizzoli. Cancer J 1991;4:335-42.
13. Magrath IT, Sandlund JT. A phase II study of ifosfamide in the treatment of recurrent sarcomas in pediatric tumors. Contr Oncol 1987;26:114-24.
14. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Fornuer R, et al. Ifosfamide with mesna uroprotection and etoposide; an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8.
15. Kung FH, Pratt CB, Krischer J. Ifosfamide and VP-16 in the treatment of recurrent malignant solid tumors of childhood: a phase II study [abstract 1174]. Proc ASCO 1989;8:301.
16. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna in 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-31.
17. Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol 1992;10:1737-42.
18. Gobel V, Jurgens H, Etspuler G, Kemperdick H, Jungblut RM, Stienen U, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987;113:187-91.
19. Enneking WF, Spanier SS, Goodman MA. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 1980;62:1027-30.
20. Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, et al Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993;11:1763-9.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
22. Mantel N. Evaluation of survival data and two new rank ' order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
23. Dunst J, Jurgens H, Sauer R, Pape H, Paulussen M, Winkelmann W et al. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995;4:919-30.
24. Craft AW, Cotterill S, Imeson J. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide: a UKCCSG/MRC Study. Am J Pediatr Hematol Oncol 1993;15:31-5.
25. Bacci G, Avella M, McDonald D, Toni A, Orlandi M, Campanacci M. Serum lactate dehydrogenase (LDH) as a tumor marker in Ewing's sarcoma. Tumori 1988;74:649-55.
26. Bereton DH, Simon R, Pomeroy TC. Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. Ann Intern Med 1975;83,352-4.
27. Parley FA, Healey JH, Caparos-Sison B, Godbold J, Lane J, Glasser DB. Lactate dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcoma. Cancer 1987;59:1245-8.
28. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83:1460-70.
29. Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt R, et al. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol 1991;9:1495-9.
30. Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, et al. Very-high-dose short-term chemotherapy for poor risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995;13:2796-804.
31. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating risks. Med Pediatr Oncol 1994; 23:86-98.
32. Grier H, Krailo M, Link M, Tarbell N, Fryer C, Pritchard D, et al. Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), adriamycin (Ad), cyclophosphamide (C), and actinomycin (A): a Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) report [abstract 1443]. Proc ASCO 1994;13:421.